NOVEL OPHTHALMIC SOLUTION TO TREAT OCULAR MANIFESTATIONS OF EPIDERMOLYSIS BULLOSA

$4,288,290FY2024Defense Health AgencyDOD

Eliksa Therapeutics, Inc.

Investigators

View source on USAspending →